Paolo A. Bruzzi - Epidemiology

Author Information

Paolo A. Bruzzi is a distinguished researcher affiliated with the Department of Epidemiology, Biostatistics and Clinical Trials at the IRCCS Ospedale Policlinico San Martino in Genoa, Italy. His work primarily focuses on epidemiology and clinical trials, contributing significantly to the medical field, particularly in areas related to cancer treatment and management of infectious diseases such as COVID-19.

Research Contributions

Paolo A. Bruzzi has made substantial contributions to medical research, demonstrated by his involvement in numerous studies and clinical trials. His work spans various critical areas, including the management of COVID-19, particularly outside intensive care units, and the treatment of different types of cancer such as breast and prostate cancer. Noteworthy is his involvement in randomized trials and guidelines development for treatment protocols, highlighting his role in advancing medical practices and therapeutic approaches.

Aliases

Throughout his career, Paolo A. Bruzzi has been identified by several aliases, including P Bruzzi, P. Bruzzi, and Paolo Bruzzi. These variations are often used interchangeably in academic publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	28,210
h-index	78
Paper Count	448

Publications:

Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial

DOI: 10.1183/13993003.00025-2022

Year: 2022

Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

DOI: 10.1002/cncr.33895

Year: 2021

139P HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study

DOI: 10.1016/j.annonc.2021.08.420

Year: 2021

118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

DOI: 10.1016/j.annonc.2021.08.399

Year: 2021

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.

DOI: 10.1016/S1470-2045(21)00352-1

Year: 2021

Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

DOI: 10.1007/s40121-021-00487-7

Year: 2021

A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

DOI: 10.1007/s40121-021-00564-x

Year: 2021

Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.

DOI: 10.1016/j.cytogfr.2021.02.001

Year: 2021

Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study

DOI: 10.3390/biology10030210

Year: 2021

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system

DOI: 10.1136/bmjopen-2020-041259

Year: 2021

How Does Outdated Software Affect Data Analysis?

Who Writes Editorials?

What Career Opportunities Exist?

How is Micro Costing Conducted?

What are the Career Opportunities for Epidemiologists?

What are the Challenges in Access Management?

What is the Prevalence of Neurodevelopmental Disorders?

Why are Caregivers Important in Epidemiology?

How are Antibody Tests Used in COVID-19 Research?

What Are the Types of Attacks?

Partnered Content Networks

Relevant Topics